Tuberculosis is a global pandemic, killing someone approximately every 20 seconds —
nearly 1.5 million in 2013 alone.
The Pandemic
A Global Threat
TB is global. The WHO estimates that two billion people — one third of the world’s population —
are infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes the disease. M.tb’s
unique cell wall, which has a waxy coating primarily composed of mycolic acids, allows the bacillus
to lie dormant for many years. The body’s immune system may restrain the disease, but it does not destroy it.
TB+HIV
Despite enormous advances in provision of services in recent years, TB’s deadly synergy with HIV/AIDS and a
surge in drug-resistant strains are threatening to destabilize gains in TB control. While incidence is
stable or falling in many regions of the world, global rates of new infections are still rising in many
endemic areas where TB goes hand-in-hand with HIV/AIDS and the effects of poverty.
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipisicing elit
-
LOREM IPSUM
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. -
DOLOR SIT AMET
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore. -
LOREM IPSUM
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. -
DOLOR SIT AMET
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore.
“Today’s TB drug regimen takes too long to cure, is too complicated to administer, and can be toxic.
Despite the flaws with and growing resistance to current TB treatments, simpler and faster cures have not been developed.”
—Mel Spigelman, M.D. President and Chief Executive Officer of the TB Alliance
Inadequate Treatment
Today’s TB drug regimen takes too long to cure, is too complicated to administer, and can be toxic.
Despite the flaws with and growing resistance to current TB treatments, simpler and faster cures have not been developed.
-
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. -
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore. -
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Help the Fight Against TB
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore
The TB Alliance
TB Alliance was conceived at a February 2000 meeting in Cape Town, South Africa, where 120 representatives
from academia, industry, major agencies, non-governmental organizations, and donors gathered to discuss the
need for new TB treatments. At the time, there were no TB drugs in clinical development and, therefore, little
hope for better cures. Participants stressed the need for new TB drugs, highlighted the unprecedented scientific
opportunities, and underscored the lack of market incentive for pharmaceutical companies to develop new TB treatments.
The resulting “Declaration of Cape Town” [.pdf – 31kb] provided a road map for TB drug development, outlining the need
for the creation of TB Alliance.
(Embedded voice, work in progress)
Our Impact
Assembled and manage the largest portfolio of potential new TB drugs in history, which includes more than 20
active development programs and 9 novel classes of drugs.
Launched the first clinical trials to test multiple new TB drugs in combination, and new TB regimens in
TB and MDR-TB patients simultaneously.
Established a robust Community Engagement program surrounding TB drug trials that create important links between
the local clinical trial sites and the TB research community.
Reinvigorated global TB drug development by being a central resource for and lowering the barriers associated
with the field — there are now 10 clinical TB drug candidates in the global portfolio, many managed by some of
the world’s largest pharmaceutical companies.
Worked in partnership with Janssen Pharmaceuticals to help develop Sirturo, the first new drug approved for
the treatment of MDR-TB.
Co-founded the Critical Path to TB Drug Regimens (CPTR) initiative, and leads the drug development arm of the
program. This initiative is working to tackle a broad array of challenges, including reducing the timeline
needed to develop novel TB regimens by as much a 75%.